We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

By LabMedica International staff writers
Posted on 25 Feb 2025
Print article
Image: The paper-based device generates high-quality samples of dried plasma, enabling accurate measurements of HIV viral load (Photo courtesy of Charlie Mace/Tufts)
Image: The paper-based device generates high-quality samples of dried plasma, enabling accurate measurements of HIV viral load (Photo courtesy of Charlie Mace/Tufts)

In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices that absorb and preserve the sample for analysis in distant laboratories. While these devices have been beneficial for monitoring medication adherence and tracking disease progression, many of the most commonly used options do not regulate the amount of blood they collect, which can lead to inaccurate results regarding a patient’s infection. Recognizing this limitation, researchers have developed a new paper-based device with wax-printed patterns that form precise channels and collection spots, ensuring a consistent volume of blood is collected every time.

A team from Tufts University School of Medicine (Medford, MA, USA) collaborated with the National Institute for Communicable Diseases (NICD, Johannesburg, South Africa) to carry out a clinical pilot involving 75 HIV-positive patients in South Africa. The NICD provided valuable real-world data, enabling Tufts researchers to compare their plasma spot cards in a clinical environment where they would be actively used. The plasma spot card developed by Tufts' research team demonstrated a more accurate measurement of a patient’s HIV infection than the widely used Roche plasma spot card (90.5% vs. 82.7%).

Published in the Proceedings of the National Academy of Sciences, the study also found that the Tufts device was better at detecting drug-resistant viral mutations (63% vs. 42%), which can inform physicians about whether to continue or change a patient's medication regimen. The researchers are now working to expand the use of this technology by forming partnerships with laboratories and researchers both in the U.S. and internationally. They are also refining the device to improve its accuracy and functionality while progressing toward its commercialization.

“We intentionally focus on developing technologies that are simple, both in construction and operation,” said Charlie Mace, an associate professor at Tufts University’s Department. “Those kinds of restrictions can make research more difficult, but ultimately we believe in that approach, because simplicity should lead to accessibility and affordability, which are both clearly needed in health care.”

Related Links:
Tufts University School of Medicine
NICD

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.